Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

$2.70B

Industries

Biotechnology,Health Care,Life Science,Medical

Founded date

Jan 1, 2010

Number Of Employee

5001 - 10000

Operating Status

Active

Stock Symbol

nasdaq:BGNE

Legal Name

BeiGene, Ltd.

Also Known As

百济神州科技有限公司,百济神州,Baiji Shenzhou

Investor Type

PE,Venture Capital

BeiGene is a global biotechnology company that is discovering and developing innovative oncology medicines that are more accessible and affordable to patients worldwide. The company is expediting development of its broad and diverse pipeline of novel therapeutics through its internal capabilities and collaborations to fulfill its commitment to radically improving access to medicines for more patients who need them. BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 60 countries as a treatment for blood cancers.

BeiGene was founded in 2010 and has grown to more than 9,000 colleagues across the globe, one of the largest oncology research teams in the world. The Company has administrative offices on three continents, including in Cambridge, MA.

BeiGene’s pipeline of cancer therapeutics includes both small molecules and biologics targeting a wide range of cancer types and stages, including hematologic malignancies and solid tumors.

To most efficiently advance its pipeline of innovative medicines, BeiGene has built extensive internal clinical development capabilities. The company is rapidly expanding its in-house manufacturing capabilities to support an agile and responsive network to deliver its medicines to the patients who need them.

BeiGene has had 1 exits. BeiGene most notable exits include Leap Therapeutics